Foxp 3 downregulation in NSCLC mediates epithelial-mesenchymal transition via NF-κ B signaling

Xi Wang,Y. Liu,L. Dai,Qi Liu,L. Jia,Huan Wang,X. Jing,Meng Liu,L. Pengfei,Zhe Cheng

2016-01-01

Abstract:Forkhead box P3 (Foxp3) is a member of forkhead box transcription factor family and it was identified as a tumor suppressor in various solid tumors. This study evaluated the expression of Foxp3 in non-small cell lung cancer (NSCLC) and investigated its role in epithelial-mesenchymal transition (EMT) of cancer cells. qRT-PCR and western blot analysis were used for examining the expression of Foxp3 in NSCLC tissues and the non-tumor tissues. A tissue microarray was constructed and scored for evaluating the clinical significance of Foxp3 expression in NSCLC tissues. RNAi was employed for downregulating Foxp3 expression and cell proliferation was done with MTT assay. Transwell with or without basement membrane matrix was used for cell migration and invasion assay respectively. Foxp3 was found downregulated in NSCLC tissues compared with non-tumoral tissues; downregulation of Foxp3 predicted adverse tumor stage and overall survival; silencing of FOXP3 promoted the proliferation, migration and invasion ability of NSCLC cells and influenced the expression level of EMT-associated proteins. However, forced expression of Foxp3 could reverse this effect. Moreover, Foxp3 could interact with LMO2 and affect the expression level of TAL1, which was in accordance with the findings in T-cell acute lymphoblastic leukemia. By screening the signalling pathways, we observed an obvious upregulation of phosphorylated NF-κB in A549 and H520 cells after silencing of FOXP3. Our results suggest that Foxp3 suppressed NSCLC cell metastasis, at least partially, via NF-κB signaling. Introduction Lung cancer remains the leading cancer killer in developed countries with intricate etiologies and unfavorable prognosis (1). According to the statistical results of International Agency for Research on Cancer (IARC), there were around 1.8 million new lung cancer cases worldwide in 2012, accounting for 13% of all new cases (2). Surgery, radiotherapy and chemotherapy are all potential suitable treatment methods for lung cancer (3). Surgical resection is the most preferred method for lung cancer treatment and a considerable proportion of lung cancer patients could be cured by standardized tumor resection. However, surgical treatment is only suitable for the early stage (I-II period) or some III stage patients whose tumors were confined to one side of the chest (4). In addition, surgery, radiotherapy and chemotherapy can be used alone or together due to different tumor types or tumor stages. Chemotherapy is most applicable for small cell lung cancer (SCLC) while non-small cell lung cancer (NSCLC), the most common type of lung cancer, can be treated with surgery, chemotherapy, radiotherapy or a combination method depending on different tumor progression. Despite the health status of lung cancer patients have been much improved due to advanced surgical techniques and adjuvant therapy, the overall survival (OS) status of NSCLC is still unsatisfactory (5,6). Targeted therapy, referring to design of appropriate treatment according to definite protein or gene target, was considered as the most effective treatment method for advanced-stage cancer patients (7,8). Several lung cancer-related therapeutic targets have been identified and the targeted drugs including growth factor receptor inhibitors, angiogenesis inhibitors and signal transduction inhibitors have been put into use for lung cancer, especially for NSCLC patients (9-11). However, the clinical efficacy of these drugs remains to be validated and there is still an urgent need to investigate novel molecular targets of NSCLC. Forkhead box P3 (Foxp3), a key member of forkhead box transcription factor family, has been considered as a remarkable modulator of regulatory T cells (Treg) (12,13). Previous studies had indicated that Foxp3 gene mutation can cause severe autoimmune diseases (14). Recently, the relationship between Foxp3 and tumoral diseases has drawn much attention. Fleskens et al provided initial evidence for a novel role Foxp3 downregulation in NSCLC mediates epithelial-mesenchymal transition via NF-κB signaling XI WANg, YINg LIu, LINgLINg DAI, QI LIu, LIuQuN JIA, HuAN WANg, LIN AN, XIAOgANg JINg, MENg LIu, PENgFEI LI and ZHE CHENg Department of Respiratory Disease, The First Affiliated Hospital of Zhengzhou university, Zhengzhou, Henan 450000, P.R. China Received March 10, 2016; Accepted August 9, 2016 DOI: 10.3892/or.2016.5024 Correspondence to: Dr Zhe Cheng, Department of Respiratory Disease, The First Affiliated Hospital of Zhengzhou university, 1 Jianshe East Road, Zhengzhou, Henan 450000, P.R. China E-mail: zhecheng2016@163.com